Avricore Health (AVCRF) Gains from Sales and Divestitures (2014 - 2021)

Avricore Health (AVCRF) posted quarterly Gains from Sales and Divestitures of $12.9 million for Q4 2021, up 11221061431.96% YoY from N/an in Q4 2020, and little changed sequentially from $12.9 million in Q3 2021.

Avricore Health (AVCRF) Gains from Sales and Divestitures (2014 - 2021) Analysis & Trends

Avricore Health has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $12.9 million for Q4 2021.

  • In Q4 2021, Gains from Sales and Divestitures rose 11221061431.96% year-over-year to $12.9 million; the TTM figure through Dec 2021 stood at $12.9 million (up 11221061431.96% YoY), while the FY2021 annual figure was $13.0 million, up 11597481837.23% from the prior year.
  • Gains from Sales and Divestitures steadied at $12.9 million in Q4 2021, from $12.9 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for AVCRF reached as high as $13.2 million in Q2 2021 and fell as low as $0.12 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Waters 31,055.11 Bn 31,054.65 Bn 1.11 Bn
2 Thermo Fisher Scientific 191.02 Bn 187.77 Bn 7.74 Bn
3 Danaher 137.16 Bn 131.47 Bn 3.59 Bn
4 Idexx Laboratories 42.82 Bn 42.62 Bn 722.74 Mn
5 Natera 39.09 Bn 37.99 Bn 696.04 Mn
6 Agilent Technologies 37.61 Bn 35.81 Bn 990.00 Mn
7 Iqvia Holdings 34.23 Bn 32.25 Bn 1.36 Bn
8 Illumina 28.14 Bn 26.98 Bn 721.00 Mn
9 Mettler Toledo International 26.40 Bn 26.33 Bn 555.82 Mn
10 Avricore Health - - -

Historic Data

Download Data
DateValue
Dec 31, 2021 12.91 Mn
Dec 31, 2021 12.91 Mn
Sep 30, 2021 12.93 Mn
Sep 30, 2021 12.93 Mn
Jun 30, 2021 13.24 Mn
Jun 30, 2021 13.24 Mn
Dec 31, 2020 0.12
Dec 31, 2020 0.12
Mar 31, 2015 3.57 Mn
Mar 31, 2015 3.57 Mn
Jun 30, 2014 3.71 Mn
Jun 30, 2014 3.71 Mn